OR WAIT null SECS
January 02, 2026
Article
The 2025 cholangitis year in review covers PBC and PSC advances, FDA designations, trial data, and evolving treatment pathways.
Podcast
This episode spotlights how advancements in 2025, including data from AASLD 2025, set the stage for future standards of care in cholestatic liver disease.
December 25, 2025
The hepatology year in review highlights FDA approvals, MASH therapies, viral hepatitis advances, cholestatic disease shifts, and evolving clinical guidance.
December 24, 2025
Explore five pivotal FDA decisions set for early 2026 that could transform specialty medicine and enhance treatment options across various conditions.
The hepatitis year in review covers FDA approvals, HBV and HDV breakthroughs, HCV label expansion, clinical guidelines, and vaccine policy changes.
December 23, 2025
The MASH/MASLD year in review highlights FDA approvals, resmetirom data, semaglutide, pemvidutide, and advances in fibrosis and noninvasive endpoints in 2025.
December 19, 2025
Positive topline results from the phase 2b IMPACT trial show statistically significant improvements in key noninvasive tests with pemvidutide.
December 17, 2025
AASLD and AST have released 2 new guidelines on evaluating adult liver transplant candidates and managing non-graft complications after transplantation.
December 15, 2025
Findings link GLP-1 RA use to reduced HCC risk in patients with type 2 diabetes, with benefits partly attributable to avoiding insulin's potential hepatotoxicity.
December 10, 2025
Reau and Brown discuss the recent CDC APIC decision to remove the universal birth-dose hepatitis B vaccine for infants born to mothers who test negative for HBV.
